LifeMD (LFMD)
(Real Time Quote from BATS)
$6.74 USD
0.00 (0.00%)
Updated Jul 30, 2024 01:48 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LFMD 6.74 0.00(0.00%)
Will LFMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LFMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LFMD
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
LFMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
LifeMD, Inc. (LFMD) Reports Q4 Loss, Tops Revenue Estimates
Lilly (LLY) Starts Website to Help Access Tirzepatide Drugs
Doximity (DOCS) Surpasses Q1 Earnings and Revenue Estimates
Other News for LFMD
LifeMD to Report Second Quarter 2024 Financial Results on August 7
LifeMD to Participate in Two Investor Conferences During August
Medifast to Announce Financial Results for the Second Quarter Ended June 30, 2024
Craig-Hallum Sticks to Their Buy Rating for LifeMD (LFMD)
Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing